Aenova Holding GmbH

Berger Strasse 8-10
82319 Starnberg
Germany

LinkedIn
Contact WebSite

Aenova is a reliable partner and a worldwide leader in drug product man­ufacturing and formulation development services. As one of the world’s largest CDMOs, Aenova offers a full range of dosage forms and integrated packaging services as well as pharmaceutical services including clinical trial supply, analytical and formulation development services. The company, headquartered near Munich, operates 15 production sites and sev­eral sales offices in ten countries around the world. More than 4,300 employees contribute to the group’s success.

Article

Motivation, Innovation, and the Power of Collaboration
14.05.2025 • TopicsInnovation

Motivation, Innovation, and the Power of Collaboration

Leading the Way in Pharmaceutical Manufacturing by Fostering an Agile Mindset and an Inclusive Culture.

Aenova Launches Program to Accelerate Pharmaceutical Development
07.05.2025 • News

Aenova Launches Program to Accelerate Pharmaceutical Development

Aenova announces the launch of its Aenovation program. This initiative aims to accelerate the early development of pharmaceutical formulations.

How CDMOs Can Contribute to Pharma Supply even Better
14.09.2023 • TopicsChemistry

How CDMOs Can Contribute to Pharma Supply even Better

The demand for medicines is increasing rapidly and R&D pipelines have doubled over the last decade.

Vaccine Filling at the Highest Level
16.04.2021 • TopicsInnovation

Vaccine Filling at the Highest Level

Recent studies show that contract manufacturers for the pharmaceutical industry, so-called CDMOs (contract development and manufacturing organizations), have so far been little involved in the production of vaccines. This is changing with the outbreak of the Covid-19 pandemic.

Aenova Expands Production Capacities in Germany
15.10.2020 • News

Aenova Expands Production Capacities in Germany

The construction of a new production building of over 3,100 m2 on the company premises started in April 2020. The start of operations is planned for mid-2021.